Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877110 · ClinicalTrials.gov registry record · Phase 1
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT00877110: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00877110 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00877110, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
Funding Source - FDA OOPD FDR004128 The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8. The NK cells must come from a family member who shares half of the HLA proteins which are immune proteins important in transplant. NK cells are a type of white blood cell. They can recognize and kill abnormal cells in the body and can work together with antibodies to kill target cells. The antibody 3F8 specifically recognizes a protein present on the target cancer cell.
Interventions
- DRUG cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2009-04-02 |
| Est. Completion | 2019-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877110
The ClinicalTrials.gov registry entry for NCT00877110 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8 is the first listed.
NCT00877110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00877110 about?
NCT00877110 is a clinical study titled "Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma". Funding Source - FDA OOPD FDR004128 The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8. The NK cells must come from a family member who shares half of the HLA proteins which are immune proteins important in transpl...
What is the current status of trial NCT00877110?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2009-04-02. Estimated completion is 2019-01-07.
What interventions are being tested in trial NCT00877110?
The interventions under investigation include: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8 (DRUG).
Who is sponsoring clinical trial NCT00877110?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.